Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Cerdelga“
Suchtreffer
Begriffe & Kennungen
Cerdelga
Eintrag öffnenCerdelga · 4.1 Therapeutic indications · 1
Eintrag öffnenCerdelga · 4.3 Contraindications · 1
Eintrag öffnenCerdelga · 4.3 · Cerdelga is contraindicated in CYP2D6 EMs with severe hepatic impairment and in CYP2D6 EMs with mild or modera
Eintrag öffnenCerdelga · 4.3 · Cerdelga is contraindicated in patients who are CYP2D6 IMs or EMs taking a strong or moderate CYP2D6 inhibitor
Eintrag öffnenCerdelga · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCerdelga · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenCerdelga · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenCerdelga · 4.5 · 5 Agents that may increase eliglustat exposure
Eintrag öffnenCerdelga · 4.5 · 6 eliglustat 2.4- and 3.0-fold, respectively. Use of a moderate CYP3A inhibitor with eliglustat is not recomme
Eintrag öffnenCerdelga · 4.5 · Agents that may decrease eliglustat exposure
Eintrag öffnenCerdelga · 4.5 · Agents whose exposure may be increased by eliglustat
Eintrag öffnenCerdelga · 4.5 · At 84 mg once daily dosing with eliglustat in PMs, it is predicted that concomitant use of moderate CYP3A inhi
Eintrag öffnenCerdelga · 4.5 · At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP2D
Eintrag öffnenCerdelga · 4.5 · At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP3A
Eintrag öffnenCerdelga · 4.5 · CYP2D6 inhibitors in EMs with mild or moderate hepatic impairment See sections 4.2, 4.3 and 4.4.
Eintrag öffnenCerdelga · 4.5 · CYP2D6 inhibitors in EMs with severe hepatic impairment See sections 4.2 and 4.3.
Eintrag öffnenCerdelga · 4.5 · CYP2D6 inhibitors in IMs and EMs After repeated 84 mg twice daily doses of eliglustat in non-PMs, concomitant
Eintrag öffnenCerdelga · 4.5 · CYP2D6 inhibitors used simultaneously with CYP3A inhibitors In IMs and EMs At 84 mg twice daily dosing with el
Eintrag öffnenCerdelga · 4.5 · CYP2D6 substrates After a single 50 mg dose of metoprolol, a CYP2D6 substrate, concomitant administration of r
Eintrag öffnen